Details for Patent: 11,998,542
✉ Email this page to a colleague
Which drugs does patent 11,998,542 protect, and when does it expire?
Patent 11,998,542 protects CONTRAVE and is included in one NDA.
This patent has fifty patent family members in thirty-six countries.
Summary for Patent: 11,998,542
| Title: | Compositions and methods for reducing major adverse cardiovascular events |
| Abstract: | The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE. |
| Inventor(s): | Preston Klassen, Kristin Taylor |
| Assignee: | Nalpropion Pharmaceuticals LLC |
| Application Number: | US17/099,316 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Recent additions to Drugs Protected by US Patent 11,998,542
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE | 200063 | Sep 10, 2014 | RX | Yes | ⤷ Start Trial | ⤷ Start Trial | U-1583 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,998,542
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200063-001 | Sep 10, 2014 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,998,542
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 098631 | ⤷ Start Trial | |||
| Argentina | 120476 | ⤷ Start Trial | |||
| Australia | 2014360492 | ⤷ Start Trial | |||
| Brazil | 112016012755 | ⤷ Start Trial | |||
| Canada | 2932127 | ⤷ Start Trial | |||
| Chile | 2016001362 | ⤷ Start Trial | |||
| China | 105899210 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
